Yes Migy119 - it will or might get way worst before they get better revenues.
This is the hard reality points:
- we are in a risk averse period, - Biotechs are high risk segments to begin with, - Revenue is key to any company, let alone OSX - they are below par at this stage, so they have a very low fair value - They have low to no cash, further dilution is possible. Investors know this.
Until they show revenue growth, all their prospects are fluff talk. It might work out - but we have to wait for a few years and track them.
OSX Price at posting:
5.2¢ Sentiment: Hold Disclosure: Held
